Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.72 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.72 |
| ▸ | DHFR | P00374 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11555328 | 0.94 | P2RX3 (0.81) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL11559756 | 0.91 | P2RX3 (0.65) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL1494157 | 0.88 | P2RX3 (0.73) | P2RX3P2RX2DHFRHTTMEN1 | |
| Ormetoprim SCHEMBL93810 | 0.88 | P2RX3 (0.69) | P2RX3P2RX2DHFRHTTMEN1 | |
| Ormetoprim SCHEMBL29389444 | 0.88 | P2RX3 (0.69) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL30215873 | 0.88 | P2RX3 (0.73) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL2150300 | 0.87 | P2RX3 (0.67) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL2150191 | 0.85 | P2RX3 (0.70) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL1494010 | 0.84 | P2RX3 (1.00) | P2RX3P2RX2DHFRHTTMEN1 | |
| SCHEMBL30215812 | 0.84 | P2RX3 (1.00) | P2RX3P2RX2DHFRHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6211185-B1 | ADMINISTERING ORALLY WITH DRINKING WATER | VETERINARY PHARMACY CORPORATION | 2001-04-03 | — | — | US | claimed |
| US-8231375-B2 | Process and apparatus for continuous wet granulation of powder material | UNIVERSITEIT GENT (BE) | 2012-07-31 | — | — | US | disclosed |
| EP-2407156-A2 | Aqueous coacervate compositions suitable for making powders and water-soluble formulations of biologically-active agents | Universiteit Gent (BE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110294864-A1 | AQUEOUS COACERVATE COMPOSITIONS SUITABLE FOR MAKING POWDERS AND WATER-SOLUBLE FORMULATIONS OF BIOLOGICALLY-ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2011-12-01 | — | — | US | disclosed |
| EP-2376061-A1 | AQUEOUS COACERVATE COMPOSITION COMPRISING POORLY WATER-SOLUBLE BIOLOGICALLY-ACTIVE AGENTS | Universiteit Gent (BE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110060020-A9 | PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2011-03-10 | — | — | US | disclosed |
| WO-2010081815-A1 | AQUEOUS COACERVATE COMPOSITION COMPRISING POORLY WATER-SOLUBLE BIOLOGICALLY-ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2010-07-22 | — | — | WO | disclosed |
| US-20090326078-A1 | PROCESS FOR PREPARING A SOLID DOSAGE FORM | UNIVERSITEIT GENT (BE) | 2009-12-31 | — | — | US | disclosed |
| US-20090318519-A2 | PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2009-12-24 | — | — | US | disclosed |
| EP-2034965-A2 | PROCESS FOR PREPARING A SOLID DOSAGE FORM | UNIVERSITEIT GENT (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2003053470-A2 | PULSED BIO-AGENT DELIVERY SYSTEMS BASED ON DEGRADABLE POLYMER SOLUTIONS OR HYDROGELS | UNIVERSITEIT GENT (BE) | 2003-07-03 | — | — | WO | disclosed |
| US-20020183287-A1 | Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution | STROBEL MICHAEL A (US) | 2002-12-05 | — | — | US | disclosed |
| US-6410543-B1 | MICROBIOCIDES; MIXTURE OF ANTIOXIDANT, SWEETENER AND FLAVOR | PHARMACEUTICAL SOLUTIONS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-0416722-B1 | Pharmaceutical compositions having differential drug release rate | PITMAN MOORE LTD (GB) | 1994-09-28 | — | — | EP | disclosed |
| US-5190760-A | Drugs for bactericides and anthelmintics | COOPERS ANIMAL HEALTH LIMITED (GB) | 1993-03-02 | — | — | US | disclosed |
| US-5063219-A | Anticoccidial composition | HOFFMANN-LA ROCHE INC. (US) | 1991-11-05 | — | — | US | disclosed |
| US-4996198-A | Mixture of 2,4-diamino-5-(trisubstituted)benzyl-pyrimidine potentiated sulfonamide antibiotic with an ionophorous polyether | HOFFMANN-LA ROCHE INC. (US) | 1991-02-26 | — | — | US | disclosed |
| US-4795639-A | ANTI-PROTOZOA TREATMENT | BURROUGHS WELLCOME CO. (US) | 1989-01-03 | — | — | US | disclosed |
| US-4156725-A | MICROBIOCIDES | BURROUGHS WELLCOME CO. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4073786-A | BACTERIOSTAT | BURROUGHS WELLCOME CO. (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183287-A1 | Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution | DPYD, DUS2, DHPS | P2RX3 1098/4885P2RX2 378/4885DHFR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.